GREENLEE, WINNER and SULLIVAN, P.C.

5370 Manhattan Circle, Suite 201 Boulder, Colorado 80303 USA Telephone (303) 499-8080 Fax (303) 499-8089

FACSIMILE COVER SHEET

DATE:

October 20, 2003

TOTAL NO. PAGES:

5 -- including cover sheet

TO:

Examiner Fay - Art Unit 1614

FIRM:

U.S. Patent and Trademark Office

FACSIMILE NUMBER:

703-746-3175

FROM:

Susan K. Doughty

RE:

DRAFT AMENDED CLAIMS

U.S. Patent Application No.: 09/712,612

Our Docket No. 90-99

If transmission is unclear, please telephone (303) 499-8080 immediately and ask for Cathy.

COMMENTS:

Attached are proposed amended claims 1 and 24 in preparation for our telephone interview scheduled for Wednesday, October 22, 2003. I will call you at 2PM Eastern time (12 noon Mountain time).

Thank you, Susan Doughty

CONFIDENTIALITY NOTICE

This message is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged and confidential. If the reader of this message is not the intended recipient or the agent responsible for delivering the message to the intended recipient, you are hereby notified that any disclosing, copying, distributing or the taking of any action in reliance on the contents of this communication is prohibited. If you have received this communication in error, please notify us immediately by telephone (call collect) and return the original to us at the above address via the postal service. Thank you.

X is independently O, NR, N or S;

Y is independently O, NR, N or S;

Z is independently C, N, S or O;

a is 0 or 1;

R1, R3, R4 and R5 are, independently, R,

wherein R is independently H, OH, alkyl, alkenyl or alkynyl, an aromatic ring system, amino, sulfnydryl, or sulfonyl, M is a divalent alkyl, alkenyl or alkynyl, aromatic ring system, or sulfonyl, W is Cl, F, Br or OCl, and A is an aromatic ring system;

 R^2 , R^8 and R^9 are independently R as defined above; and

R⁶ is independently R, NH₂, OH, or OCOR where R is as set forth above;

R⁷ is independently OH or H; or

R⁶ and R⁷ taken together are O;

and pharmaceutically acceptable salts or esters of the foregoing, as well as optical isomers thereof.

Claim 24 (currently amended): A method of treating an ocular diabetic complication selected from the group consisting of: loss of PKC in eye lens cells, polyol accumulation in the eye, galactitol formation from galactose in lens cells, vascular leakage in the eye, and expression of aldose reductase in the retina comprising administering to a patient with diabetes an effective amount of one or more compounds of the formula:

or

$$\begin{array}{c|c}
C & X & R^1 \\
R_a^6 & R^2 & Y
\end{array}$$

$$\begin{array}{c|c}
R_a^6 & R^3 &$$

wherein:

T is independently CR, NR, N, S or O;

T is independently CR, NR, N, S or O;

X is independently O, NR, N or S;

Y is independently O, NR, N or S;

Z is independently C, N, S or O;

a is 0 or 1;

R¹, R³, R⁴ and R⁵ are, independently, R,

wherein R is independently H, OH, alkyl, alkenyl or alkynyl, an aromatic ring system, amino, sulfhydryl, or sulfonyl, M is a divalent alkyl, alkenyl or alkynyl, aromatic ring system, or sulfonyl, W is Cl, F, Br or OCl, and A is an aromatic ring system;

R², R⁸ and R⁹ are independently R as defined above; and

R⁶ is independently R, NH₂, OH, or OCOR where R is as set forth above;

R⁷ is independently OH or H; or

R⁶ and R⁷ taken together are O;

and pharmaceutically acceptable salts or esters of the foregoing, as well as optical isomers thereof.

Serial number 09/712,612

Claim 1 (currently amended): A method of <u>reducing aldose reductase activity preventing</u> cataracts, retinopathy, lens cell damage and retinal cell damage caused by diabetes comprising administering to a patient an effective amount of one or more compounds of the formula:

$$\begin{array}{c|c}
R^{4} & & \\
R_{a}^{5} & & \\
R_{a}^{8} & & \\
R_{a}^{9} & & \\
\end{array}$$

OI

$$\begin{array}{c|c}
C & X & R^1 \\
R_a^6 & R^7 & R^2 & Y
\end{array}$$

$$\begin{array}{c|c}
R_a^8 & Z & R_a^3 & R^3 &$$

wherein: